Drug intelligence / Profile preview

ADVM-082

Development stage: Preclinical
Lead developer: Adverum Biotechnologies
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies
Administration: Intravitreal

Overview

ADVM-082 is an investigational intravitreal gene therapy designed to treat achromatopsia, a rare inherited retinal disorder characterized by color vision defects. The therapy uses Adverum's proprietary AAV.7m8 capsid to deliver a functional CNGB3 gene directly into the eye, aiming to restore cone function and improve visual outcomes in affected individuals. It was initially developed by Adverum Biotechnologies and is currently in preclinical development[1][2][7].

Other names: AAV.7m8-CNGB3 gene therapy

Targets

CNGB3 (Cyclic nucleotide-gated channel beta 3)

Beyond the preview

Go deeper on ADVM-082.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADVM-082.

Explore the full profile